Sarcoma  >>  carotuximab IV (ENV-105)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carotuximab IV (ENV-105) / Kairos Pharma
NCT01975519: A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma

Checkmark Presentation of updated data of Votrient + TRC105 in angiosarcoma at CTOS conference 2016
Nov 2016 - Nov 2016: Presentation of updated data of Votrient + TRC105 in angiosarcoma at CTOS conference 2016
Checkmark Presentation of data from P1b/2 trial in combination with TRC105 for soft tissue sarcoma at ASCO 2016
Jun 2016 - Jun 2016: Presentation of data from P1b/2 trial in combination with TRC105 for soft tissue sarcoma at ASCO 2016
Checkmark P1b data in combination with TRC105 for sarcoma at ASCO 2015
More
Completed
2a
111
US
TRC105 and Pazopanib, Chimeric Antibody (TRC105) to CD105, Votrient
Tracon Pharmaceuticals Inc.
Advanced Soft Tissue Sarcoma
03/19
03/19

Download Options